Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991;41(3):187-96.
doi: 10.1007/BF00315428.

Evaluation of three methods of symptom reporting in a clinical trial of felodipine

Affiliations
Clinical Trial

Evaluation of three methods of symptom reporting in a clinical trial of felodipine

M A Wallander et al. Eur J Clin Pharmacol. 1991.

Abstract

251 patients from 23 primary health care centres were recruited to a clinical trial in which either felodipine or placebo was added to baseline metoprolol treatment. Three methods of symptom reporting were used in 191 patients, namely two previously documented self-administered questionnaires and an adverse event monitoring system (spontaneous reports to treating physician). Higher frequencies of symptoms were seen with the questionnaires compared to spontaneous reporting. However, the overlap between the methods was moderate and they were found to complement one another. The questionnaires were completed twice during the study and the adverse event monitoring system was applied on five occasions. The rate of application had consequences for the ability of each method to detect transient, dose-related symptoms, e.g. headache and dizziness. Regardless of method, the possibility of detecting dose-related symptoms was enhanced when symptoms were measured not only during active treatment but also during a run-in or other baseline period, and both phases were considered in the analyses.

PubMed Disclaimer

Similar articles

Cited by

References

    1. CMAJ. 1989 Jun 15;140(12):1441-8 - PubMed
    1. Int J Clin Pharmacol Biopharm. 1979 Sep;17(9):405-9 - PubMed
    1. Br J Clin Pharmacol. 1984;18 Suppl 2:189S-195S - PubMed
    1. Eur J Clin Pharmacol. 1987;32(1):71-5 - PubMed
    1. J Cardiovasc Pharmacol. 1985;7 Suppl 1:S137-45 - PubMed

LinkOut - more resources